FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
The SHARON trial is a phase 1 study testing a new treatment called GO-4 for patients with advanced pancreatic cancer who have ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional ...
Large-scale drug atlas uncovers new genome editing modulators and potential therapeutic strategies for DNA repair-deficient ...
MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as ...
Known as Breast Circulating Methylation Assay (BCMA), the new blood test looks for tumour DNA released into the bloodstream ...
Yale epidemiologist Harvey Risch, who has entertained a connection between Covid vaccines and “turbo cancer” and promoted ...
UC San Diego researchers uncover enzyme behind cancer genome chaos, pointing to potential therapies for aggressive tumors.
First CTA authorization marks nChroma’s transition to a clinical-stage company; first patient dosing in Phase 1/2 trial planned for early 2026 Preclinical studies demonstrated CRMA-1001 delivers ...
Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...
Early and sustained ctDNA clearance in early breast cancer treated with neoadjuvant HER2-targeted therapy tracks closely with pathologic complete response to treatment and 3-year outcomes.
UC San Diego scientists have identified the enzyme that shatters cancer genomes and helps them evolve to resist treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results